This website uses cookies and similar technologies to provide the best functionality and display content according to your interests on our site and social networks.

We respect your privacy and process information only for marketing and functional purposes if you give us your consent by clicking ‘I accept.’
You can change your cookie settings at any time by clicking on the privacy settings.

Terms of use
Privacy Notice
Settings
This website uses cookies and similar technologies to provide the best functionality and display content according to your interests on our site and social networks.

We respect your privacy and process information only for marketing and functional purposes if you give us your consent by clicking ‘I accept.’
You can change your cookie settings at any time by clicking on the privacy settings.

Terms of use
Privacy Notice
This cookie is used for system purposes only and does not track user actions. It is required for normal functioning of this web site.
This is a web analytics service.
Processing company
  • Google Ireland Limited
  • Google Building Gordon House, 4 Barrow St, Dublin, D04 E5W5, Ireland
Data Purposes
  • Marketing
  • Advertisement
  • Web Analytics
Technologies Used
  • Cookies
  • Pixel Tags
Data Attributes
  • IP address (anonymised)
  • Browser information (browser type, referring/exit pages, the files viewed on our site, operating system, date/time stamp, and/or clickstream data)
  • Usage Data (views, clicks)
Data Collected
This list represents all (personal) data that is collected by or through the use of this service.
  • IP address
  • Date and time of visit
  • Usage data
  • Click path
  • App updates
  • Browser information
  • Device information
  • JavaScript support
  • Pages visited
  • Referrer URL
  • Downloads
  • Flash version
  • Location information
  • Purchase activity
  • Widget interactions
Legal Basis
  • In the following the legal basis for the processing of personal data required by Art. 6 I 1 GDPR is listed.
  • Art. 6 (1) (a) GDPR
Location of Processing
  • Republic of Serbia
Retention Period
  • The data will be deleted as soon as they are no longer needed for the processing purposes.
Data Recipients
  • Alphabet Inc.
This is a Tracking technology offered by Facebook and used by other Facebook services such as Facebook Custom Audiences.
Processing company
  • Facebook Ireland Limited
  • 4 Grand Canal Square, Grand Canal Harbour, Dublin, D02, Ireland
Data Purposes
  • advertising
  • Marketing
  • Retargeting
  • Analyse
  • Tracking
Technologies Used
  • Cookies
Data Attributes
  • Pixel specific data
  • Http-Header
  • Optional Parameters
Data Collected
This list represents all (personal) data that is collected by or through the use of this service.
  • Facebook user ID
  • Browser information
  • Usage data
  • Geräteinformationen
  • Non-sensitive custom data
  • Referrer URL
  • Pixel ID
  • Location information
  • Pixel specific data
  • User behaviour
  • Ads viewed
  • Interactions with advertisement, services, and products
  • Marketing information
  • Content viewed
  • IP address
Legal Basis
  • In the following the legal basis for the processing of personal data required by Art. 6 I 1 GDPR is listed.
  • Art. 6 para. 1 s. 1 lit. a GDPR
Location of Processing
  • Republic of Serbia
Retention Period
  • The data will be deleted as soon as they are no longer needed for the processing purposes.
Data Recipients
  • Facebook Inc.
Hemofarm Achieves Double-digit Growth in 2023
08. December 2023.
As a result of an ongoing investment in all the resources, Hemofarm has achieved a double-digit growth with 7.8 billion produced units in 2023, bringing another year to an end as a regional leader, as mentioned at the company’s New Year’s reception.


Hemofarm company_photo-Ownership of Hemofarm company

‘In this year, Hemofarm has invested more than 36 million EUR, and additional 100 million EUR have already been envisaged for the forthcoming period. The planned investment will make our company a mega-factory, even globally. This is yet another confirmation of our commitment to the Serbian market and the Western Balkans region’, said Ronald Seeliger, Chief Executive Officer of Hemofarm, expressing big expectations in the coming period. He added that with its products, Hemofarm is present in almost 40 markets around the globe and is one of the largest pharmaceutical manufacturers in this region.

Hemofarm, a member of STADA Group, presently stands out as a leading company not only in business, but also in the field of sustainable development in Serbia and region wide. Caring for patients’ needs, Hemofarm has, this year as well, expanded its portfolio of products for treatment and prevention of various diseases.

The year was abundant with numerous jubilees, as Hemofarm’s PROBIOTIC brand has celebrated 20 years of existence, as the top and best-selling probiotic in the Serbian market. Hemofarm Banja Luka has marked 20 years of operation of the solid dosage forms factory, while Hemofarm Foundation has celebrated 30 years of work. Hemofarm has been awarded several times for numerous socially responsible projects this year, and Hemofarm Foundation’s campaign ‘The Most Important Call in Life’ has been presented with 11 awards.


CARING DAY

Within the global STADA Group’s Caring Day action, more than 200 Hemofarm employees in Serbia, Bosnia and Herzegovina and Montenegro took part in the voluntary blood donation action. Caring Day is organized in tune with the corporate purpose Caring for people’s health as a trusted partner. Hemofarm employees in Serbia have donated blood in an organized manner in Belgrade, Vršac and Šabac aimed at promoting the donorship as the most humane act. Ever since 2005 to date, Voluntary Blood Donation Sections at Hemofarm, boasting almost 850 members, have donated blood more than 100 times in the organized actions, thereby collecting around 6,200 units of this precious bodily fluid.

Hemofarm employees in the action on the Caring Day _photo author - Marko Risović


STADA EXPO, a multi-media platform, enabling the visitors to fully experience sustainable development in a unique way and get to know how Hemofarm fights for a better future of all, was presented in October. After Vršac, Romania, Montenegro, Šabac and Banjaluka, STADA EXPO has continued it tour across numerous European countries, and it will be available to the general public in Serbia in 2024.

‘We will keep on developing Hemofarm as a modern and responsible company and educating others on that journey of ours, as the forerunner of sustainable development in this region. Please rest assured that we will continue being the most determined fighters for people's health’, said Ronald Seeliger.

With a share of more than 70% of the total export of pharmaceutical products from the country, Hemofarm is one of the top Serbian exporters. It operates on four continents and has a team of over 4000 employees. As a STADA Group member, Hemofarm is one of the biggest German investments, with more than 450 million EUR invested in Hemofarm since 2006 alone.


Ronald Seeliger, Sanda Savić, Veljko Pešić at the New Year’s reception of Hemofarm_photo author-Goran Zlatković